Lifeward Ltd. Reports 22% Revenue Decline and Widened Operating Loss in Q1 2026

Lifeward Ltd. reported its financial results for the first quarter of 2026, revealing a revenue of $3.9 million, a decrease of 22% from $5.0 million in the same period last year. The company's gross profit also fell to $1.3 million from $2.1 million, reflecting a gross margin decline attributed to increased operating expenses. The operating loss for the quarter widened to $10.3 million compared to a loss of $4.9 million in the prior year, primarily due to a significant rise in research and development costs, which surged to $5.8 million from $0.9 million.

The company's total assets increased to $33.4 million as of March 31, 2026, up from $22.9 million at the end of 2025. This growth was driven by a substantial rise in cash and cash equivalents, which reached $11.4 million, compared to $2.2 million at the end of the previous fiscal year. Lifeward's liabilities also rose significantly, with total liabilities increasing to $27.1 million from $14.5 million, largely due to the issuance of convertible promissory notes and warrant liabilities related to its recent acquisition of Oratech Pharmaceuticals Ltd.

Strategically, Lifeward has made notable advancements, including the acquisition of Oratech in March 2026, which is expected to enhance its portfolio in biomedical technologies. This acquisition included intellectual property related to ORMD-0801, an oral insulin candidate, and is part of Lifeward's broader strategy to diversify its product offerings beyond its existing rehabilitation devices. The company also rebranded from ReWalk Robotics to Lifeward in January 2024, reflecting its expanded focus on comprehensive healthcare solutions.

Operationally, Lifeward's customer base and product engagement metrics indicate a challenging environment. The company reported a negative operating cash flow of $3.7 million for the quarter, raising concerns about its ability to sustain operations without additional funding. Lifeward's accumulated deficit has now reached $295.5 million, and management has expressed substantial doubt about the company's ability to continue as a going concern for at least the next 12 months without securing further capital.

Looking ahead, Lifeward plans to pursue additional financing to support its operations and product development initiatives. The company is also focused on integrating Oratech into its operations and achieving expected efficiencies. However, management has indicated that ongoing market conditions, including inflationary pressures and geopolitical tensions, may impact future performance. Lifeward's ability to navigate these challenges will be critical as it seeks to stabilize its financial position and capitalize on growth opportunities in the healthcare sector.